Combination Chemotherapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
First Line Treatment of Metastatic Hormone Refractory Prostate Cancer With a Combination of Novantrone-Navelbine
Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group
This PHASE2 trial investigates Prostate Cancer and is currently ongoing. GERCOR - Multidisciplinary Oncology Cooperative Group leads this study, which shows 7 recorded versions since 1999 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE2
▶ Show 2 earlier versions
-
Feb 2018 — Jun 2018 [monthly]
Unknown Status PHASE2
-
Jan 2017 — Feb 2018 [monthly]
Unknown Status PHASE2
First recorded
May 1999
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GERCOR - Multidisciplinary Oncology Cooperative Group
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Amiens, France
- • Clichy, France
- • Levallois-Perret, France
- • Marseille, France
- • Paris, France
- • Reims, France
- • Senlis, France
- • Toulon, France